Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2359)

VOLUNTARY ANNOUNCEMENT

DISMISSAL OF 1260H LITIGATION

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the "**Company**", "**WuXi AppTec**" or "**we**") on a voluntary basis.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, November 17, 2026

As of the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.

* *For identification purposes only*

DISMISSAL OF 1260H LITIGATION

Reference is made to the Company's announcement dated November 10, 2026. Following such announcement, we received the formal notice from the United States Department of Defense (the "**DoD**") to remove the Company as a "Chinese military company" in the DoD's Section 1260H list and such removal has taken effect from November 10, 2026 (U.S. time).

On November 13, 2026 (U.S. time), the Company and the DoD filed a joint stipulation of dismissal with the United States District Court for the District of Columbia (the "**Court**") to dismiss the litigation seeking removal of the Company from the Section 1260H list (the "**1260H Litigation**"). Such stipulation was subsequently approved by the Court on November 16, 2026 (U.S. time).

We are thankful for the collaborative team efforts to achieve this result. We are grateful for the trust and support from our customers and partners during this process. We will continue to work hard for our customers and the patients they serve, and continue to operate with integrity in pursuit of our vision that every drug can be made and every disease can be treated.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.